Literature DB >> 3907686

Urinary pseudouridine excretion in myelomatosis.

S H Sørensen, D A Brown, E H Cooper, K A Kelly, I C MacLennan.   

Abstract

Urinary psi excretion is independent of the main indices of tumour activity in myelomatosis (serum paraprotein, serum beta 2-microglobulin, serum creatinine and urinary light chain production). The mean (+/- s.d.) psi at presentation was 40.7 +/- 22.6 nmol. mumol ucr-1, compared to 25.4 +/- 4.8 nmol. mumol ucr-1 in controls. Urinary psi levels at presentation are significantly related to prognosis, the higher the level the poorer the prognosis. However, when these levels have been stratified according to the corresponding level of serum beta 2m, the level adds little as a prognostic factor.

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 3907686      PMCID： PMC1977279          DOI： 10.1038/bjc.1985.270

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


  16 in total

1.  Age dependence of human urinary pseudouridine excretion.

Authors:  G L Tritsch; J M Luch; J T Evans; A Mittelman
Journal:  Biochem Med       Date:  1979-12

Review 2.  Chemical nature, properties, location, and physiological and pathological variations of modified nucleosides in tRNAs.

Authors:  G Dirheimer
Journal:  Recent Results Cancer Res       Date:  1983

3.  Evaluation of carcinoembryonic antigen, tissue polypeptide antigen, placental alkaline phosphatase, and modified nucleosides as biological markers in malignant lymphomas.

Authors:  T Rasmuson; G R Björk; L Damber; S E Holm; L Jacobsson; A Jeppsson; B Littbrand; T Stigbrand; G Westman
Journal:  Recent Results Cancer Res       Date:  1983

4.  Rapid, quantitative high-performance liquid column chromatography of pseudouridine.

Authors:  K C Kuo; C W Gehrke; R A McCune; T P Waalkes; E Borek
Journal:  J Chromatogr       Date:  1978-05-01

5.  Differential excretion of modified nucleosides in adult acute leukemia.

Authors:  D A Heldman; M R Grever; R W Trewyn
Journal:  Blood       Date:  1983-02       Impact factor: 22.113

6.  Urinary excretion of modified nucleosides in chronic myelogenous leukemia.

Authors:  D A Heldman; M R Grever; C E Speicher; R W Trewyn
Journal:  J Lab Clin Med       Date:  1983-05

7.  New applications of urinary nucleoside markers.

Authors:  E Borek; O K Sharma; T P Waalkes
Journal:  Recent Results Cancer Res       Date:  1983

8.  A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival.

Authors:  B G Durie; S E Salmon
Journal:  Cancer       Date:  1975-09       Impact factor: 6.860

9.  The prognostic value of serum beta 2 microglobulin compared with other presentation features in myelomatosis.

Authors:  J Cuzick; E H Cooper; I C MacLennan
Journal:  Br J Cancer       Date:  1985-07       Impact factor: 7.640

10.  Evaluation of serum beta 2-microglobulin as a prognostic indicator in myelomatosis.

Authors:  J A Child; S M Crawford; D R Norfolk; J O'Quigley; J H Scarffe; L P Struthers
Journal:  Br J Cancer       Date:  1983-01       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.